News Column

Epilepsy Foundation to Collaborate with Intellimedix and Pfizer

July 19, 2014

The Epilepsy Foundation is developing a drug discovery platform for genetic forms of epilepsy in collaboration with Intellimedix and Pfizer Inc.

"This collaboration has the potential to benefit all individuals and families living with epilepsy, especially the one-third of people with epilepsy who live with uncontrolled seizures despite all currently available therapies," said Philip Gattone, President and CEO of the Epilepsy Foundation, in a release. "With this drug discovery platform and our new collaboration, the Foundation furthers its mission to unify the epilepsy community and embrace innovation in new therapies."

"We are thrilled by this collaboration that aims to develop and apply novel drug screening technologies to deliver personalized therapies to patients with epilepsy," said Daniel Fischer, President and CEO of Intellimedix. "We will strive to significantly improve the lives of patients with Dravet Syndrome in the very short term."

"We are excited to be part of this collaboration because we believe that future therapies will be more tailored to an individual's needs," said Ruth McKernan, Head of Neusentis, Pfizer's research unit for pain and sensory disorders. "Collaborating with organizations like the Epilepsy Foundation is so important because they bring us closer to patients."

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Professional Services Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters